Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)

Table 5 Adverse events

Event	Grade 1	Grade 2	Grade 3
Special interest categories
Hypoglycemia	6 (7.1%)	2 (2.4%)	0 (0.0%)
Volume depletion	2 (2.4%)	0 (0.0%)	0 (0.0%)
Urinary tract/genital infection	0 (0.0%)	1 (1.2%)	0 (0.0%)
Cutaneous symptom	0 (0.0%)	0 (0.0%)	0 (0.0%)
Others
Cold	2 (2.4%)	4 (4.7%)	0 (0.0%)
Influenza	0 (0.0%)	3 (3.5%)	0 (0.0%)
Pollenosis	1 (1.2%)	2 (2.4%)	0 (0.0%)
Hypertension	0 (0.0%)	2 (2.4%)	0 (0.0%)
Angina pectoris	0 (0.0%)	0 (0.0%)	1 (1.2%)
Cataract	0 (0.0%)	0 (0.0%)	1 (1.2%)
Retinal detachment	0 (0.0%)	0 (0.0%)	1 (1.2%)
Vitreous surgery due to retinopathy	0 (0.0%)	0 (0.0%)	1 (1.2%)
Cough variant asthma	0 (0.0%)	1 (1.2%)	0 (0.0%)
Elevated LDL	0 (0.0%)	1 (1.2%)	0 (0.0%)
Fever	0 (0.0%)	1 (1.2%)	0 (0.0%)
Fracture	0 (0.0%)	1 (1.2%)	0 (0.0%)
Hemorrhagic stool	0 (0.0%)	1 (1.2%)	0 (0.0%)
Hordeolum	0 (0.0%)	1 (1.2%)	0 (0.0%)
Prostatitis	0 (0.0%)	1 (1.2%)	0 (0.0%)
Elevated CK	1 (1.2%)	0 (0.0%)	0 (0.0%)
Nausea	1 (1.2%)	0 (0.0%)	0 (0.0%)
Odontectomy	1 (1.2%)	0 (0.0%)	0 (0.0%)
Pruritus	1 (1.2%)	0 (0.0%)	0 (0.0%)
Thamuria	1 (1.2%)	0 (0.0%)	0 (0.0%)
Wobbliness	1 (1.2%)	0 (0.0%)	0 (0.0%)

Values are n (%)
Evaluation of adverse events (AEs) was performed based on Common Terminology Criteria for Adverse Event version 4.0. Grade 1: mild (no need for therapeutic intervention); Grade 2: moderate (needs therapeutic intervention in outpatient clinic); Grade 3: severe (needs therapeutic intervention by admission); Grade 4: life threatening, or places the participant, in the view of the investigator, at immediate risk of death from the experience as it occurred; Grade 5: death. AEs of Grade 4 or 5 were not reported
LDL low-density lipoprotein cholesterol, CK creatine kinase

ISSN: 1475-2840